Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission

Autolus Therapeutics plc

2025-Q3 EPS reported -$0.74 vs consensus -$0.23 ▼ miss (-221.5%)

Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).
Cash, equivalents and marketable securities $367.4M at Sept 30, down from $588.0M at Dec 31, 2024.
FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL; Phase 1 CATULUS data show 95% ORR.
Phase 1 CARLYSLE data in lupus nephritis: 83% DORIS remission, no ICANS/high-grade CRS; Phase 2 LUMINA start expected by year-end.
Leadership bolstered: Cintia Piccina US CCO, Miranda Neville CTO, Patrick McIlvenny CAO.

item 2.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.